But again, I think if I had to put pen to paper and think about a timeline that should be important, it should be by the end of 2025, second half of 2025, we should be in a good position to look back and say, how is our strategy working and how is it enhancing the value for our shareholders. So that was the first question, I believe, Louise. The second question is on lemzo outside of China. As you can imagine, as we’ve said before, right, that AbbVie had terminated the development, global development of lemzo, but we have the rights to China. So we continue the trial in China. At this time, we have no plans to initiate a study until we see the interim data, we analyze the class data of the other CD47 targeting agents, and we meet with an expert panel to be able to understand if our molecule is truly differentiated from the other CD47, and we can come back at that time, Louise, to clearly articulate as to if we’re going to move forward with lemzo or the backup compound.
And then the last question, Louise, was on the — sorry…
Louise Chen: Conferences. Anything on the — aside from ESMO, I know you mentioned givastomig from ESMO, but any other of your main compounds going to be presenting new data at conferences throughout the remainder of the year?
Raj Kannan: As far as we know, I don’t think there’s anything that jumped out to us for the rest of the year, but I’ll let John comment on it. John?
John Hayslip: Yeah. Thank you. So as we mentioned, we plan to present the givastomig dose escalation clinical findings at the European Society of Medical Oncology in October this year. Also, as I mentioned, we anticipate the dose expansion cohort, the continued enrollment of patients with gastric GEJ, and esophageal cancer. We expect to have interim results early next year from that cohort of patients. So we’ll be reviewing those results and bringing those forward as quickly as possible. But for the remainder of 2023, no additional conferences to add at this time.
Louise Chen: Okay. Great. Thank you very much.
Raj Kannan: Thank you, Louise.
Tyler Ehler: Thank you, Louise. The next question we will direct to Ethan Markowski. Ethan, please go ahead.
Gil Blum: Hi, everyone. This is actually Gil, not Ethan. So maybe a quick one on the commercial opportunity for eftan. Are you guys thinking of pricing it similar to the current standard of care in China, if you had any thoughts there?
Raj Kannan: Hi, Gil. I think it would be a little premature right now to comment on price. But I do know that we’re excited about the profile of the compound itself in terms of the benefit that it could bring to patients. And we’re excited about the growing large commercial opportunity that we have available for the human growth hormone product. So I think we’re going to price it competitively. I can definitely assure you that, but I think it’s a little too early for us to actually comment on price publicly before we’ve even filed the product.
Gil Blum: Okay. And maybe a quick biology question on givastomig. So signaling for 4-1BB usually requires trimerization of the ligand, which links to these weird-looking bell curves, a little bit like the hook effect. I’m just wondering, have you seen that in preclinical studies with givastomig or is this even an issue? Thank you.
Raj Kannan: John, do you want to take that?
John Hayslip: Sure. Yeah. Thanks, Gil. Good to hear from you. So this has not been a non-clinical — is not a preclinical issue for givastomig. And further in the early clinical findings, we continue to see systemic pharmacodynamic effect of soluble 4-1BB in a predictive manner. So we’ve been quite confident about what we’ve observed today with givastomig regarding the PD effect.
Gil Blum: [Indiscernible] questions.
Raj Kannan: Thank you, Gil.
Tyler Ehler: Next up, I would like to direct the next question to Andres Maldonado. Andres, please go ahead.
